2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 147 filers reported holding 2SEVENTY BIO INC in Q2 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,829,077 | -49.4% | 475,085 | -29.7% | 0.00% | -50.0% |
| Q1 2024 | $3,613,567 | -64.1% | 675,433 | -71.3% | 0.00% | -50.0% |
| Q4 2023 | $10,064,697 | -29.6% | 2,357,072 | -35.4% | 0.00% | -42.9% |
| Q3 2023 | $14,304,727 | -51.8% | 3,649,165 | +24.5% | 0.01% | -50.0% |
| Q2 2023 | $29,659,453 | +149581.8% | 2,930,776 | +50.9% | 0.01% | +27.3% |
| Q1 2023 | $19,815 | +54.9% | 1,942,618 | +42.3% | 0.01% | +57.1% |
| Q4 2022 | $12,794 | -99.9% | 1,365,391 | +78.1% | 0.01% | 0.0% |
| Q3 2022 | $11,155,000 | +58.6% | 766,657 | +43.9% | 0.01% | +75.0% |
| Q2 2022 | $7,034,000 | +15.8% | 532,871 | +49.7% | 0.00% | +33.3% |
| Q1 2022 | $6,073,000 | +142.1% | 355,962 | +263.8% | 0.00% | +200.0% |
| Q4 2021 | $2,508,000 | – | 97,839 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 5,953,825 | $23,338,994 | 3.82% |
| Newtyn Management, LLC | 3,076,490 | $12,059,841 | 2.98% |
| DAFNA Capital Management LLC | 1,447,465 | $5,674,063 | 1.76% |
| CHI Advisors LLC | 1,002,007 | $3,927,867 | 1.56% |
| AlphaCentric Advisors LLC | 657,500 | $2,577,400 | 1.46% |
| Casdin Capital, LLC | 2,023,913 | $7,933,739 | 0.88% |
| Madison Avenue Partners, LP | 1,494,125 | $5,856,970 | 0.83% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $5,522,892 | 0.62% |
| Eversept Partners, LP | 1,453,378 | $5,697,242 | 0.48% |
| Engine Capital Management, LP | 341,870 | $1,340,130 | 0.30% |